Navigation Links
Clinical trial at GHSU Cancer Center targets advanced prostate cancer
Date:12/3/2012

AUGUSTA, Ga. Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.

The trial, led by GHSU Cancer Center Director Samir N. Khleif, is the first in the country to investigate prostate cancer treatment combining Provenge with two other cancer-fighting drugs, CT-011 and cyclophosphamide. As the first FDA-approved immunotherapy treatment for prostate cancer, Provenge has been found to extend life expectancy of certain men with advanced prostate cancer by nearly 20 percent.

"Although the increased overall survival seen with Provenge treatment is a welcome advance in the treatment of prostate cancer, the goal of cancer therapy must be the eradication of disease," said Khleif. "Therefore, improvements can be made, and this clinical trial is intended to improve the current standard of care."

Provenge works by training the body's immune system to find and attack prostate cancer cells. Khleif's trial hopes to boost Provenge's effectiveness by combining it with two other drugs: CT-011, a type of antibody that reverses immune suppression caused by cancer, and cyclophosphamide, which in a low dose enhances the effect of Provenge and CT-011. Both have been safely used alone or in combination with other cancer therapies, but never for prostate cancer.

Preclinical animal studies in Khleif's lab found that the combination of Provenge with these two other drugs led to a significant increase in survival and complete tumor regression in more than 50 percent of mice. Based on these results, Dendreon Corporation, the makers of Provenge, and Khleif are collaborating on this first in human trial.

Khleif joined the GHSU Cancer Center as its Director after more than 22 years in the Cancer Vaccine Section at the National Cancer Institute. His lab focuses on research into vaccines to help the immune system target and eradicate cancers.

Prostate cancer is the most common cancer and the second leading cause of cancer deaths among men in most Western countries.


'/>"/>

Contact: Christen Carter
chrcarter@georgiahealth.edu
706-721-5733
Georgia Health Sciences University
Source:Eurekalert  

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. Clinical insight improves treatment with new lung cancer drug
3. Clinical news alert from the American Academy of Orthopaedic Surgeons
4. NYU Langone experts present research, clinical advances at neurosurgeons meeting
5. Kroenke honored for outstanding contributions in clinical research training
6. Awards celebrate clinical research that can improve health and alleviate suffering
7. Association for Psychological Science, SAGE launch Clinical Psychological Science
8. URMC clinical trial tests new regimen for hypertension
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clinical trial at GHSU Cancer Center targets advanced prostate cancer
(Date:1/20/2017)... ... , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that are ... Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains 44 ... flare and light leak transitions have a very high-dynamic range for super smooth falloff. ...
(Date:1/20/2017)... ... 20, 2017 , ... “I Forgive You”: a fine examination of how God handles sin, ... creation of published author, Stephen Miller, who, for over ten long years has been waiting ... Born in Trinidad and Tobago, he has been serving the Lord for over twenty years, ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children ... the simple and achievable answer. “The Land of More and More” is the creation ... in Angola, Indiana where he works with the children’s ministry department. , Michael ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy Network announced ... their 503A compounding pharmacy located in Ocala, Florida. , Meeting the Needs ... throughout the United States for high-quality human anti-aging and wellness compounded medications, ...
(Date:1/19/2017)... ... January 19, 2017 , ... Remote ... recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound System. ... to RMT technology that delivers HD, dynamic, streaming ultrasound images and video to ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... , Jan. 20, 2017 Wells Specialty Pharmacy announces ... Howell Branch Rd in Winter Park, Florida ... Park . Operations have been consolidated into the 3796 ... also pleased to announce that Chad Tomlinson , former ... the Company effective immediately. Mr. Tomlinson is a Graduate of ...
(Date:1/20/2017)... , January 20, 2017 Avillion LLP, a ... of Mark Weinberg , MD MBA as Chief Medical Officer. ... USA . ... Dr Weinberg has spent more than 17 years as ... pharma companies to micro-cap biotech. Over the course of his career, ...
(Date:1/19/2017)... Jan. 19, 2017 The global immunomodulators ... by 2025, according to a new study by ... to be predominantly driven by high R&D investments ... large-scale production of new and therapeutically advanced drugs. ... drugs at an unprecedented rate into the immunomodulators ...
Breaking Medicine Technology: